Answers are grounded in this paper and cite their sources.
The incorporation of rituximab into the hyper-CVAD regimen appears to improve outcome for younger patients with CD20-positive Ph-negative precursor B-lineage ALL.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: